Target intelligence / Profile preview

Partially hydrolyzed guar gum (PHGG)

Target
PHGG
Molecular classification
Other (dietary fiber, polysaccharide)
01

Overview

Partially hydrolyzed guar gum (PHGG) is a soluble dietary fiber derived from the endosperm of the guar bean, composed mainly of galactomannans (mannose backbone with galactose side chains) that has undergone enzymatic hydrolysis to reduce viscosity. PHGG is not digested in the upper gastrointestinal tract, but is selectively fermented by colonic microbiota, promoting the growth of beneficial bacteria such as Bifidobacterium and Lactobacillus, and leading to increased production of health-promoting short-chain fatty acids (SCFAs) like butyrate. PHGG is used as a prebiotic to improve bowel habits in conditions such as irritable bowel syndrome (IBS), constipation, and diarrhea, and has secondary benefits on lipid and glucose metabolism, mineral absorption, and potentially other systemic disorders. PHGG is not a receptor, enzyme, or conventional drug target, but acts indirectly by modulating the gut microbiota. Key point: This is not a molecular or receptor target, but a complex dietary fiber exerting therapeutic benefits via prebiotic modulation of the gut environment.

Other names
PHGGpartially hydrolyzed guarhydrolyzed guar gumguar fiber
02

Mechanism of action

Fermentation by colonic bacteria leads to increased beneficial bacteria (Bifidobacterium, Lactobacillus, butyrate-producing species); Increases production of short-chain fatty acids that improve intestinal health; Modulates gut motility and stool consistency via microbiota-mediated mechanisms.

03

Biological functions

Prebiotic activityRegulation of gut microbiota compositionPromotion of short-chain fatty acid production (e.g., butyrate, acetate, propionate)Improvement of bowel habits (constipation/diarrhea relief)Support of intestinal barrier function
04

Disease associations

Functional gastrointestinal disorders (e.g., irritable bowel syndrome, chronic constipation, diarrhea)Metabolic disorders (e.g., hyperlipidemia, abnormal glucose metabolism)Other (potential benefits in chronic kidney disease, fatty liver, systemic inflammation in animal models)
05

Safety considerations

Generally well tolerated; occasionally mild gastrointestinal discomfort reported
06

Biomarkers

Microbiota composition changes (increased Bifidobacterium, Lactobacillus, SCFA-producers)Fecal short-chain fatty acid concentrationsBristol Stool Scale for bowel habit assessment

Beyond the preview

Go deeper on Partially hydrolyzed guar gum (PHGG).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Partially hydrolyzed guar gum (PHGG).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call